{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:27:09Z","timestamp":1784903229270,"version":"3.55.0"},"reference-count":15,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Influenza Resp Viruses"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In a post\u2010hoc analysis of the phase 3 BLOCKSTONE study (JapicCTI\u2010184180), we investigated household transmission of baloxavir\u2010resistant (PA\/I38X) influenza viruses. Using baloxavir resistance rates from prior clinical trials and the rate of influenza transmission observed in the study, the predicted number of PA\/I38X transmission events was 4.8, assuming wild type and PA\/I38X viruses were equally transmissible. However, no PA\/I38X viruses were observed. These results suggest a low potential for baloxavir\u2010resistant influenza virus transmission from treated to untreated individuals, potentially due to reduced viral\/transmission fitness for PA\/I38X viruses and\/or low viral titres at the time when resistant viruses arise.<\/jats:p>","DOI":"10.1111\/irv.13079","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T21:29:10Z","timestamp":1674077350000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Investigating the transmission of baloxavir\u2010resistant influenza viruses from treated index patients to untreated household contacts in the BLOCKSTONE study"],"prefix":"10.1111","volume":"17","author":[{"given":"Joanne","family":"Harding","sequence":"first","affiliation":[{"name":"Roche Products Ltd.  Welwyn Garden City UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Bernasconi","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd.  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Williams","sequence":"additional","affiliation":[{"name":"Roche Products Ltd.  Welwyn Garden City UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9779-5740","authenticated-orcid":false,"given":"Steffen","family":"Wildum","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd.  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Shionogi &amp; Co., Ltd.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeki","family":"Uehara","sequence":"additional","affiliation":[{"name":"Shionogi &amp; Co., Ltd.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9731-3481","authenticated-orcid":false,"given":"Aeron C.","family":"Hurt","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd.  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00224\u201020"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2018.10.008"},{"key":"e_1_2_7_4_1","unstructured":"Roche.Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older.2022. Accessed October 18 2022.https:\/\/www.roche.com\/media\/releases\/med-cor-2022-08-12"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002747"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716197"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20103099(20)30004\u20109"},{"key":"e_1_2_7_8_1","unstructured":"NIID.Detection of antiviral drug\u2010resistant viruses in Japan during the 2018\/2019 influenza season.2019. Accessed October 18 2022.https:\/\/www.niid.go.jp\/niid\/images\/flu\/resistance\/20191128\/dr18-19e20191126-1.pdf"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915341"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009527"},{"key":"e_1_2_7_11_1","unstructured":"WHO.Recommended composition of influenza virus vaccines for use in the 2020 southern hemisphere influenza season.2019. Accessed October 18 2022.https:\/\/cdn.who.int\/media\/docs\/default-source\/influenza\/who-influenza-recommendations\/vcm-southern-hemisphere-recommendation-2020\/201909-recommendation.pdf?sfvrsn=f34905d9_13&download=true"},{"key":"e_1_2_7_12_1","unstructured":"WHO.Recommended composition of influenza virus vaccines for use in the 2020\u20132021 northern hemisphere influenza season.2020. Accessed October 18 2022.https:\/\/cdn.who.int\/media\/docs\/default-source\/influenza\/who-influenza-recommendations\/vcm-northern-hemisphere-recommendation-2020-2021\/202002-recommendation.pdf?sfvrsn=6868e7b3_21&download=true"},{"key":"e_1_2_7_13_1","unstructured":"WHO.Recommended composition of influenza virus vaccines for use in the 2021 southern hemisphere influenza season.2020. Accessed October 18 2022.https:\/\/cdn.who.int\/media\/docs\/default-source\/emergency-preparedness\/global-influenza-programme\/recommended-composition-of-influenza-virus-vaccines\/202009-recommendation.pdf?sfvrsn=1331fa94_2&download=true"},{"key":"e_1_2_7_14_1","unstructured":"WHO.Recommended composition of influenza virus vaccines for use in the 2021\u20132022 northern hemisphere influenza season.2021. Accessed October 18 2022.https:\/\/cdn.who.int\/media\/docs\/default-source\/influenza\/who-influenza-recommendations\/vcm-northern-hemisphere-recommendation-2021-2022\/202102_recommendation.pdf?sfvrsn=2af603d8_12&download=true"},{"key":"e_1_2_7_15_1","unstructured":"WHO.Recommended composition of influenza virus vaccines for use in the 2022\u20132023 northern hemisphere influenza season.2022. Accessed October 18 2022.https:\/\/cdn.who.int\/media\/docs\/default-source\/influenza\/who-influenza-recommendations\/vcm-northern-hemisphere-recommendation-2022-2023\/202202_recommendation.pdf?sfvrsn=5c88e006_13&download=true"},{"key":"e_1_2_7_16_1","unstructured":"ClinicalTrials.Gov.Study to assess the efficacy of baloxavir marboxil versus placebo to reduce onward transmission of influenza A or B in households.2022. Accessed October 18 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03969212"}],"container-title":["Influenza and Other Respiratory Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/irv.13079","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/irv.13079","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/irv.13079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T17:25:22Z","timestamp":1692465922000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/irv.13079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1111\/irv.13079"],"URL":"https:\/\/doi.org\/10.1111\/irv.13079","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/IRV.13079\/v1\/decision1","asserted-by":"object"}]},"ISSN":["1750-2640","1750-2659"],"issn-type":[{"value":"1750-2640","type":"print"},{"value":"1750-2659","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"2022-11-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13079"}}